

Submitter: Tracy Townsend

On Behalf Of:

Committee: House Committee On Behavioral Health and Health Care

Measure, Appointment or Topic: HB2387

March 21, 2025

House Committee on Behavioral Health and Health Care

900 Court Street NE

Salem, Oregon 97301

RE: HB 2387 - Oregon Psilocybin Program Improvement Bill

Chair Nosse, Co-Chairs Javadi and Nelson, and Committee Members,

Thank you for the opportunity to submit testimony in strong support of HB 2387, the Psilocybin Program Improvement Bill.

My name is Dr. Tracy Kim Townsend, and I am a licensed medical doctor and licensed psilocybin facilitator based in Portland, Multnomah County]. I have devoted my career to helping patients navigate healing from intergenerational trauma and complex health challenges, and Oregon's psilocybin therapy program is one of the most promising and innovative tools we have in this effort.

Since Oregon voters passed Measure 109, I have worked directly with clients seeking relief from PTSD, anxiety, depression, addiction, and existential distress.

Many of these individuals have exhausted conventional medical options. In my work, I've seen firsthand how access to legal, regulated psilocybin services—delivered in a safe, structured environment—can help people reconnect with meaning, foster self-compassion, and experience lasting shifts in their mental and emotional well-being.

HB 2387 introduces essential improvements that support both safety and access:

1. Legal protections for licensed healthcare professionals who are also licensed facilitators, allowing them to use their training during the preparation and integration phases of psilocybin services. This supports more informed consent, trauma-informed care, and better outcomes for clients.

2. Clear guidance that permits healthcare providers to discuss psilocybin therapy with patients without fear of professional discipline. This is vital to ensuring that patients receive accurate, science-based information and can make decisions collaboratively with their care teams.

3. Revised Psilocybin Advisory Board membership to include licensed facilitators and service center operators. Representation from those working directly with clients ensures that the program continues to evolve in grounded, practical, and responsible ways.

4. Required psilocin labeling and communication of potency to improve transparency and client education. Psilocin is the active compound, and accurate labeling supports appropriate dosing and reduces the risk of unexpected experiences.

I urge you to support HB 2387. These updates will strengthen the integrity of

Oregon's psilocybin therapy program, protect professionals committed to ethical healing work, and ultimately make this care more effective and accessible for the people who need it most.

Thank you for your leadership and attention to this important legislation.

Sincerely,

Dr. Tracy Kim Townsend, MD

Portland, Multnomah County, Oregon